

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Impact of under-registration of chronic kidney disease on mortality and cardiovascular outcome: a time-to-event analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-081115
Article Type:	Original research
Date Submitted by the Author:	20-Oct-2023
Complete List of Authors:	Van den Wyngaert, Ine; KU Leuven, Department of Public Health and Primary Care Mamouris, Pavlos; Katholieke Universiteit Leuven Groep Biomedische Wetenschappen, Departement of Public Health and Primary Care Ali, Endale Alemayehu; KU Leuven, Department of Public Health and Primary Care Vaes, Bert; KU Leuven, Departement of Public Health and Primary Care; Université Catholique de Louvain (UCL), Institute of Health and Society Van Pottelbergh, Gijs; Katholieke Universiteit Leuven Groep Biomedische Wetenschappen, Departement of Public Health and Primary Care
Keywords:	Chronic renal failure < NEPHROLOGY, Mortality, CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1
4
5 2
6
7 3
8
9 4
10
11 5
12
13 6
14
15 7
16
17 8
18
19 9
20
21 10
22
23 11
24
25 12
26
27 13
28
29 14 **Impact of under-registration of chronic kidney disease on mortality and cardiovascular**
30 **outcome: a time-to-event analysis**
31
32 16
33
34
35 17
36
37 18 Ine Van den Wyngaert*¹, Pavlos Mamouris¹, Endale Alemayehu Ali¹, Bert Vaes¹ and Gijs Van
38 19 Pottelbergh¹
39
40
41 20
42
43 21
44
45
46 22
47
48 23 ¹Academic Centre for General Practice, Department of Public Health and Primary Care, University of
49 24 Leuven, Leuven, Belgium.
50
51
52 25
53
54 26 *Corresponding author
55
56 27 E-mail: ine.vandenwyngaert@kuleuven.be
57
58 28
59
60 29

For peer review only

1
2
3 1 **Abstract**

4
5 2 **Background and objective**

6
7 3 Patients with impaired kidney function and increased albuminuria are at risk of developing
8
9 4 cardiovascular disease. Previous research revealed that a substantial proportion of patients with
10
11 5 chronic kidney disease do not get a registered diagnosis in the Electronic Health Record of the
12
13 6 general practitioner. The aim of this study was to investigate the association between under-
14
15 7 registration of chronic kidney disease and/with all-cause mortality and cardiovascular outcome.

16 8 **Design and setting**

17
18 9 A retrospective study in primary care.

19
20
21 10 **Methods**

22
23 11 The analyses were carried out in the INTEGO database, a general practice-based morbidity
24
25 12 registration network in Flanders, Belgium. The study used INTEGO data from the year 2018 for all
26
27 13 patients ≥ 18 years old, including 10551 patients. To assess the risk of mortality and cardiovascular
28
29 14 disease, a time-to-event analysis was performed. Cox proportional hazard model was used to
30
31 15 evaluate the association between under-registration and incidence of all-cause mortality and
32
33 16 cardiovascular events with mortality as a competing risk. Subgroup analyses were performed for
34
35 17 estimated glomerular filtration rate stages (3a, 3b, 4 and 5). Multiple imputation was done following
36
37 18 the methodology of Mamouris et al.

38
39
40
41
42
43
44 19 **Results**

45
46 20 Mortality was higher in patients with unregistered chronic kidney disease compared to patients with
47
48 21 registered CKD (HR 1.29, 95%-CI [1.19-1.41]). Under-registration of chronic kidney disease did not
49
50 22 show a higher risk to develop cardiovascular disease (HR 0.92, 95%-CI [0.77-1.11]).

51
52
53
54
55
56
57
58
59
60 23 **Conclusion**

24
25 24 An association between under-registration and all-cause mortality could be found, although this did
26
27 25 not appear to be the case for cardiovascular disease.

1 **Strengths and limitations of this study**

- 2 - To assess the risk of CVD and mortality, Cox-proportional hazard models were used and a
- 3 competing risk analysis was performed to account for the presence of competing event
- 4 (mortality).
- 5 - For the missing variables, we used multiple imputation.
- 6 - The presence of proteinuria was not taken into account in our CKD population due to the lack
- 7 of data on proteinuria.
- 8 - The study used healthcare data which may underrepresent the healthy and asymptomatic that
- 9 do not seek healthcare.
- 10 - Although the patient population is representative for the Flemish population, registering GPs
- 11 are not representative for the GP population. It is a selected group of high quality registering
- 12 practitioners which use a specific electronic health record.

13 **Keywords:** cardiovascular, chronic renal failure, mortality, survival analysis, under-registration

15 **Word count:** 3042

16 **Number of figures, tables, boxes, references:** 4 figures, 1 table, 46 references

1 Introduction

2 Chronic kidney disease (CKD) is a progressive condition that describes the gradual loss of kidney
3 function over time. A reduced estimated glomerular filtration rate (eGFR) and elevated albuminuria
4 are the two key measures in patients with CKD [1]. Multiple studies have documented suboptimal
5 albuminuria testing in CKD patients in primary care [2, 3]. However, both reduced eGFR and the
6 presence of albuminuria are associated with an increased risk of cardiovascular disease (CVD),
7 hospitalisation and premature death [4-9]. The most common causes of CKD in high-income and
8 middle-income countries are glomerulonephritis, diabetes mellitus and hypertension (the latter being
9 also a consequence of CKD) [10-12]. The increased cardiovascular risk (CVR) in patients with CKD was
10 therefore assumed to be the result of these underlying diseases. However, meta-analyses showed that
11 impaired kidney function and increased albuminuria are CVR factors, independently of the presence
12 of hypertension or diabetes mellitus [6, 13]. Kidney specific mechanisms that make significant
13 contributions to the CVR were documented [4].

14 Previous research revealed that a substantial proportion of patients did not have a registered CKD
15 diagnosis in the general practitioner's (GP) Electronic Health Record (EHR) [14, 15]. In addition,
16 mainly patients with early-stage CKD (stage 3) remained without official diagnosis [15]. Although we
17 know that patients with CKD are more at risk, the impact of not registering a diagnosis has not been
18 investigated, neither on cardiovascular outcome nor on mortality [4-6].

19 The aim of this study was to evaluate the impact of under-registration on all-cause mortality and
20 cardiovascular outcome in Flanders, Belgium.

1 **Materials and Methods**

2 **Study setting and data source**

3 This study was conducted following on from previous work [15]. In that research, the prevalence of
4 unregistered CKD, the diagnostic delay (time between abnormal eGFR and diagnosis) and the baseline
5 characteristics of the unregistered patient group were examined in a Belgian GP population. The same
6 study population was used.

7 The analyses were carried out in the INTEGO database, a general practice-based computerised
8 morbidity and mortality registration network in Flanders, Belgium, managed at the Department of
9 General Practice of the University of Leuven since 1994. Data collection is regulated by an opting-out
10 procedure. INTEGO procedures were approved by the ethical review board of the Medical School of
11 KU Leuven (N° ML 1723) and by the Belgian Privacy Commission (no SCSZG/13/079). More than 100
12 GP centres applied for inclusion in this registry. Only the data of the 86 practices (representing 454
13 GPs) with optimal registration performance (80% coded diagnoses) were included in the database.
14 Patient characteristics and diagnoses are encoded and classified using the International Classification
15 of Primary Care (ICPC-2; WHO FIC Collaborating Centre). All laboratory tests performed by GPs are
16 included in the database.

17 The methodology of data collection, study design, and analyses in the INTEGO registry have been
18 previously reported [16].

19 **Study population**

20 Guidelines for CKD management recommend that patients should be diagnosed with CKD if the
21 reduction in kidney function (eGFR <60 mL/ min/1.73 m²) is present for more than three months [1,
22 17, 18]. All patients ≥ 18 years old with two consecutive eGFR laboratory measurements indicating
23 CKD (eGFR <60 mL/min/1.73m²) recorded >90 and ≤ 730 days apart during the baseline period were
24 included. The current study used INTEGO data from the year 2018. Selected patients had at least one
25 eGFR measurement <60 mL/min/1.73m² in 2018 and belonged to the GP's yearly contact group. There
26 must be at least 12 months of continuous presence in the database prior to the first qualifying eGFR.
27 Patients were excluded if they had a solid kidney transplant (ICD-10 Z94.0) before the date of the
28 second qualifying eGFR (index date).

29 **Unregistered CKD case definition**

30 Patients with unregistered CKD were identified if they had no diagnostic CKD code for any time
31 during the ≥ 12 -month lookback period before the first eGFR measurement and up to 6 months post-
32 index date. ICPC-2 codes are used more frequently in general practice than ICD-10, so we chose to

1
2
3 1 use the ICD-10 code U99. Those with a documented U99 during this time period were considered as
4 2 having registered CKD. Since the U99 code is a collective code for unspecified kidney disease - like
5 3 chronic kidney disease, renal cyst - we manually checked both the code and the written diagnosis
6 4 whether the code did merge with CKD. It was assumed that patients with at least one diagnostic code
7 5 for CKD during the above specified time window had registered CKD.
8
9

10 6 **Statistical analysis**

11
12
13
14 7 R software (version 4.0.4) was used [19]. A descriptive analysis was performed, calculating incidences
15 8 of all-cause mortality, myocardial infarction, stroke, peripheral vascular disease and heart failure
16 9 among those with registered versus unregistered CKD. The follow-up period for these adverse clinical
17 10 outcomes started six months after the index date until observation end date (follow-up end date or
18 11 end of data coverage up to 17/07/2023, whichever came first). The variables were summarised using
19 12 patient counts with percentages. The chi-square was calculated. P values less than 0.05 were
20 13 considered significant. Subgroup analyses were performed for eGFR stages (3a, 3b, 4 and 5) and
21 14 visualised using Kaplan-Meier curves.

22
23
24
25
26
27
28 15 To assess the risk of CVD and mortality, Cox-proportional hazard models were used. A competing risk
29 16 analysis was performed to account for the presence of competing event (mortality) [20]. We
30 17 estimated the hazard and sub-distribution hazard ratios (HRs and sHRs) and their 95% confidence
31 18 interval (CI). P values less than 0.05 were considered significant. We adjusted for all possible
32 19 confounders (age, gender, hypertension, diabetes, smoking status, hypercholesterolemia, history of
33 20 CVD). We fitted the models by including and excluding covariates one-by-one (sequential method)
34 21 and we did not find significant change in the estimate and significance of covariates which were
35 22 already in the model after adding new covariate. We calculated the Variance Inflation Factor to check
36 23 for multicollinearity [21].

37
38
39
40
41
42
43 24 Variables were chosen based on the risk factors for CVD, defined by the Framingham Heart Study
44 25 [22]. Cardiovascular events were defined as myocardial infarction (ICPC-2 K75), stroke (ICPC-2 K90),
45 26 peripheral vascular disease (ICPC-2 K92) and heart failure (ICPC-2 K77). Hypertension or
46 27 hypercholesterolemia included patients with a diagnosis of hypertension (ICPC-2 K86) or
47 28 hypercholesterolemia (ICPC-2 T93) in the EHR. Antihypertensive, lipid lowering and antidiabetic
48 29 medication were defined by the ATC-codes. (Supplemental file 1) Patients with a diagnosis of
49 30 diabetes type 1 or 2 in the EHR (ICPC-2 T89 and T90) and patients taking antidiabetic drugs were
50 31 merged into the diabetes group. Since there was multicollinearity between total cholesterol, HDL
51 32 and LDL, we chose to include total cholesterol.
52
53
54
55
56
57
58
59
60

1
2
3 1 For the missing variables, we used the methodology developed by Mamouris et al [23]. Concisely, in
4 2 their work, they developed a 3-stage approach to impute longitudinal covariates so as complexities
5 3 such as convergence and collinearity are resolved [23]. We imputed Body Mass Index (BMI), total
6 4 cholesterol, systolic blood pressure (SBP) and smoking status longitudinally for years 2017-2023, thus
7 5 utilising the previous and earlier information of the same patient. (Supplemental file 2) We then
8 6 extracted the observed year 2018. The dataset was imputed 20 times and model analysis was
9 7 performed for each imputation separately. We finally pooled the results together using Rubin's rules
10 8 [24].
11 9
12 10
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1 Results

2 As reported in our first research, 231 702 patients ≥ 18 years old were detected in the INTEGO database
3 in 2018. (Supplemental file 3) Since the general practice didn't meet the criteria for best quality
4 register, 40 216 patients were excluded. Among included patients, there were 10 551 patients (5.5%)
5 with two consecutive eGFR laboratory measurements indicating chronic kidney disease (CKD) (eGFR
6 < 60 mL/min/1.73m²), recorded at least three months apart during the baseline period. Out of them,
7 7176 patients (68%) had no U99 at any time. The other 3375 patients (32%) had a registered diagnosis
8 [15].

9 Descriptive analysis

10 *Incidences*

11 Incidences of all-cause mortality, myocardial infarction, stroke, peripheral vascular disease and heart
12 failure associated with CKD diagnosis status as of index date, are being displayed in table 1.

13 *Strata analyses*

14 Figure 1 and 2 respectively display the differences in survival time and time to development of CVD in
15 patients with CKD, according to the CKD stage and presence of diagnostic code in the EHR. An
16 informative risk set table shows the number of patients who were under observation and at risk in the
17 specific period. It appeared that registered patients in stage 3B and 4 had a much better survival rate
18 than unregistered patients after 3 years of follow-up, namely 82.23% (registered group, stage 3B) and
19 72.87% (registered group, stage 4) towards 73.05% (unregistered group, stage 3B) and 59.52%
20 (unregistered group, stage 4). (Figure 1) The same difference was documented for CKD stage 5 after 1
21 year of follow-up. In the registered group, 87.88% survived at that time, towards 76.09% of the
22 unregistered patients. Only a small number of stage 5 patients were still under observation after 3
23 years of follow-up, making it difficult to interpret the results at that time. (Figure 1) Similar survival
24 curves were reported in both registered and unregistered in stage 3A.

25 Similar to the findings for mortality, less registered patients in stage 5 developed CVD compared to
26 unregistered stage 5 patients after 1 year of follow-up (morbidity rate 98.99% in the registered group,
27 towards 95.65% in the unregistered group). (Figure 2) In stage 3B and 4 were the differences in
28 morbidity rate between registered and unregistered smaller after 3 years of follow-up compared to
29 what we documented for mortality, respectively 93.80% (registered, stage 3B and 4) compared to
30 93.28% (unregistered, stage 3B) and 95.24% (unregistered, stage 4). As for mortality, stage 3A showed
31 similar results curves for unregistered and registered.

32 Time to event-analysis

1
2
3 1 Figure 3 and 4 respectively show the time to the occurrence of death or CVD with mortality as a
4 2 competing risk. Results for analyses with and without mortality as a competing risk were similar.

6
7 3 All-cause mortality analysis showed that patients with unregistered CKD, male gender, age ≥ 65 ,
8 4 diabetes, CKD stage 3B-5, history of CVD and (ex-)smokers had a higher chance of dying. Hypertension
9 5 and hypercholesterolemia were protective factors, as was the use of antihypertensive and lipid
10 6 lowering medication and BMI. The values for smoking and hypercholesterolemia were not statistically
11 7 significant. The HR for total cholesterol was equal to 1.

12
13
14
15
16 8 Considering the results for CVD, only age ≥ 65 , hypertension, antihypertensive medication, CKD stage
17 9 3B, BMI, total cholesterol and history of CVD were statistically significant. The sub-distribution hazard
18 10 ratio (sHR) for unregistered CKD was <1 . A history of CVD and hypercholesterolemia seemed to be
19 11 protective factors for CVD, while patients with hypertension had an increased risk.

20
21
22
23
24 12

peer review only

1 Discussion

2 Principal findings

3 This study showed that patients with a properly registered diagnosis die less quickly than unregistered
4 ones. However, according to our results, these patients did not appear to have a lower risk to develop
5 CVD. Besides, patients in stage 3B and 4 with a registered diagnosis had much better mortality survival
6 rates compared to the unregistered ones. The association of under-registration and CVD was less clear
7 in the different CKD stages.

8 Patients with CKD and hypercholesterolemia showed to be less associated with CVD and mortality,
9 although the result was not statistically significant. In contrast, hypertensive CKD patients appeared to
10 have a higher risk of CVD, but a lower risk of mortality. Patients with a history of CVD seemed to have
11 a lower risk of new events, but a higher risk to die.

12 Context of the results

13 Under-registration appears to be associated with all-cause mortality. However, the CaReMe CKD study
14 recently showed that the rates of cardiovascular and all-cause death were 31-49% higher in registered
15 CKD patients than in measured CKD patients, which could not be confirmed in our study [25]. Few
16 research has been conducted in this regard, making it difficult to compare.

17 The key research question of our results is what caused patients to die. Previous research showed that
18 a reduced kidney function predicts both cardiovascular and non-cardiovascular mortality due to
19 pulmonary disease, infection, cancer, and other causes [26-28]. The association between a reduced
20 eGFR and the increased risk of cardiovascular events and hospitalisation was also found [9, 12, 29].
21 Surprisingly, the unregistered group in our study did not have a higher risk of CVD than the registered.
22 It is unclear why no association was found. Possibly, this group died more frequently as a result of non-
23 CVD. On the other hand, under-registration probably extends beyond renal insufficiency and also
24 occurs with other pathologies. Mata-Casas et al. reported under-registration of diabetes mellitus in
25 Spanish primary health care [30]. Cardiovascular diagnosis may also be under-registered, so that no
26 association with under-registration could be found [31].

27 A second important question remains why the difference in mortality outcome was found between
28 registered and unregistered patients. Is the root of the problem with the GP or the patient? Our
29 previous research showed that there were small differences between registered and unregistered
30 patients at baseline [15]. Hypertension was more frequently present in the registered (64.4% of the
31 registered population) compared to the unregistered (51.7% of the unregistered population). Similar
32 results were found for type 2 diabetes (33.1% of the registered compared to 28.2% of the

1
2
3 1 unregistered). Small differences were also noticeable in the use of ACE-I or ARB (52.6% among the
4 2 registered compared to 46.3% of the unregistered) [15]. However, these small differences do not seem
5 3 to provide an adequate explanation for the difference in mortality, partly in view of the result that the
6 4 unregistered group had no higher risk of CVD.
7
8
9

10 5 Subsequently, the follow-up of these patients should be assessed. A possible explanation for the
11 6 difference in mortality between registered and unregistered groups could be that less attention was
12 7 paid while prescribing and dispensing nephrotoxic (over-the-counter) medication by the GP and
13 8 pharmacist, resulting in further deterioration of kidney function. There may have been less attention
14 9 to the CVR factors associated with impaired renal function. In that case, we also would have expected
15 10 an increase in CVD, unless, as previous described, it concerns a problem of global under-registration.
16 11 On the other hand, the responsibility of the patient in the follow-up of the disease must be brought to
17 12 attention. Possibly, the unregistered group contained a large proportion of patients who were not
18 13 adherent to follow-up and therapy, as a result of which some did not or belatedly encountered
19 14 problems. So, it is becoming increasingly important to examine these hypotheses and to involve the
20 15 patient in his care and to find out what view he has in this regard [32, 33].
21
22
23
24
25
26
27
28
29

30 16 According to our research results, hypertension in CKD patients would be a risk factor in the
31 17 development of CVD, although a protective factor in the development of all-cause mortality. Though,
32 18 we know from previous research that hypertension is a risk factor for the development of CVD and
33 19 premature death [34-36]. The reasons for this difference are unclear. We need to consider the effect
34 20 of antihypertensive medication on this outcome, since 48% of the patients took an Angiotensin-
35 21 converting-enzyme-inhibitor (ACE-I) or an Angiotensin Receptor Blocker (ARB) [15]. The beneficial
36 22 effect of these drugs on cardiovascular events and all-cause mortality has been confirmed in the past
37 23 [37]. Ettehad et al. described that in patients with CKD smaller risk reductions in cardiovascular events
38 24 were seen as a result of antihypertensive medication than in patients without CKD [38]. However, we
39 25 should also keep in mind that there may be under-registration of hypertension and SBP.
40
41
42
43
44
45
46

47 26 Additionally, it is surprising that hypercholesterolemia and total cholesterol do not show a higher risk
48 27 on CVD and mortality, since this is a proven risk factor for CVD [22]. However, this result was not
49 28 significant and may be explained by the use of lipid lowering medication, as 45% of patients were on
50 29 this medication at baseline [15]. After all, Fabbian F. et al. determined that statins are an effective
51 30 treatment in CKD patients, especially in the early stages of the disease [39]. A history of CVD appears
52 31 to be a protective factor in the development of new CVD, of which a properly adjusted therapy can be
53 32 the reason (secondary prevention) [39, 40]. In addition, we know that CKD is associated with adverse
54 33 outcomes in those with existing CVD, which includes increased mortality after an acute coronary
55 34 syndrome [41-43].
56
57
58
59
60

1
2
3 1 In our previous work, we found that the majority of patients with renal insufficiency were in stage 3,
4 with a higher proportion registered in stage 5 (75.7% registered) compared to stage 3a (22.9%
5 registered) [15]. However, this study showed major differences in survival rates between registered
6 and unregistered patients in both the earlier (3B) and further stages (4 and 5) of renal failure. The
7 importance of early detection has been described many times in the past [17, 44]. This research must
8 therefore be a plea for early detection of CKD and registration of the diagnostic code in the EHR. A
9 solution to detect unregistered patients can be found in an Audit-& Feedback system, since this has
10 proven to be effective and to have added value in primary care [45, 46].

11 **Limitations**

12 There were some limitations to note. First, we did not take the presence of proteinuria into account in
13 our CKD population. Mainly due to the lack of data on proteinuria, which brings us straight to the
14 problem of under detection of proteinuria in the Flemish general practice.

15 Subsequently, the study used healthcare data which may underrepresent the healthy and
16 asymptomatic that do not seek healthcare. The data of care refusers were included in the research
17 results.

18 Although the patient population is representative for the Flemish population, registering GPs are not
19 representative for the GP population. It is a selected group of high quality registering practitioners
20 which use a specific electronic health record. This selection bias of GPs could eventually have an
21 influence on some process parameters in the follow-up of patients [16]. In addition, data collected in
22 a real-world setting may lack information on specific covariates and laboratory investigations. Lab
23 results from the hospital and specialists are automatically entered into the EHR, but their diagnoses
24 are not. We used multiple imputation to fill in the missingness (see method section).

25

26 **Conclusion**

27 An association between under-registration and all-cause mortality could be found, although this did
28 not appear to be the case for CVD. Patients in stage 3B and 4 CKD with a registered diagnosis had much
29 better survival rates compared to the unregistered ones. It is unclear whether better registration will
30 lead to a better outcome, which means that the differences between the patient groups must be
31 further mapped out.

32

33

34

1
2
3 1 **Data availability statement:** All data generated or analysed during this study are included in this
4 2 published article [and its supplementary information files].
5

6 3 **Acknowledgements:** Not applicable.
7

8
9 4 **Funding:** This research received no specific grant from any funding agency in the public, commercial
10 5 or not-for-profit sectors .
11

12
13 6 **Authors contributions:** IVDW, PM, BV and GVP designed and conceptualized the study. EAA and PM
14 7 performed the data analysis. IVDW drafted the manuscript. IVDW, EAA, PM, BV and GVP revised the
15 8 manuscript. IVDW and GVP are the guarantors of this work. All authors read and approved the final
16 9 manuscript.
17

18
19
20 10 **Competing interests statement:** None declared.
21

22
23 11 **Patient and public involvement:** Patients or the public were not involved in the design, or conduct,
24 12 or reporting, or dissemination plans of our research
25
26

27 13

28
29 14

30
31 15

32
33 16

34
35 17

36
37 18

38
39 19

40
41 20

42
43 21

44
45 22

46
47 23
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

1. Levin A, et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl.* 2013;3(1):1-150.
2. Stevens PE, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. *Kidney Int.* 2007;72(1):92-9.
3. Allen AS, et al. Primary Care Management of Chronic Kidney Disease. *J Gen Intern Med.* 2011;26(4):386-92.
4. Gansevoort RT, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet.* 2013;382(9889):339-52.
5. Matsushita K, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet.* 2010;375(9731):2073-81.
6. Mahmoodi BK, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. *Lancet.* 2012;380(9854):1649-61.
7. Thompson S, et al. Cause of Death in Patients with Reduced Kidney Function. *J Am Soc Nephrol.* 2015;26(10):2504-11.
8. Muntner P, et al. History of myocardial infarction and stroke among incident end-stage renal disease cases and population-based controls: An analysis of shared risk factors. *Am J Kidney Dis.* 2002;40(2):323-30.
9. Go AS, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med.* 2004;351(13):1296-305.
10. De Bhailis AM, Kalra PA. Hypertension and the kidneys. *Br J Hosp Med (Lond).* 2022;83(5).
11. Xie Y, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. *Kidney Int.* 2018;94(3):567-81.
12. Webster AC, et al. Chronic kidney disease. *Lancet.* 2017;389(10075):1238-52.
13. Fox CS, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet.* 2012;380(9854):1662-73.
14. Ryan TP, et al. Chronic kidney disease prevalence and rate of diagnosis. *Am J Med.* 2007;120(11):981-6.
15. Van den Wyngaert I, et al. An exploration of under-registration of chronic kidney disease in Belgian general practices using logistic regression. *Plos One.* 2022;17(12):e0279291.
16. Truyers C, et al. The Intego database: background, methods and basic results of a Flemish general practice-based continuous morbidity registration project. *Bmc Med Inform Decis Mak.* 2014;14:48.
17. Shlipak MG, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int.* 2021;99(1):34-47.
18. Van Pottelbergh G, et al. Richtlijn voor goede medische praktijkvoering: Chronische nierinsufficiëntie. *Domus Medica.* 2012.
19. Team R. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2021.
20. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. *Bone Marrow Transplant.* 2007;40(4):381-7.
21. Tsagris M, Pandis N. Multicollinearity. *Am J Orthod Dentofacial Orthop.* 2021;159(5):695-6.
22. D'Agostino RB, et al. General cardiovascular risk profile for use in primary care: The Framingham heart study. *Circulation.* 2008;117(6):743-53.
23. Mamouris P. A longitudinal transition imputation model for categorical data applied to a large registry dataset. *Statistics in medicine.* 2023, In press.

- 1
2
3 1 24. Rubin DB, Campion WM. Multiple imputation for nonresponse in surveys. *J Mark Res.* 1989;26(4):485-6.
4 2
5 3 25. Johan S, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary
6 4 population of 2.4 million patients from 11 countries: The CaReMe CKD study.
7 5 *Lancet.* 2022;20:100438.
8 6 26. Marks A, et al. Chronic kidney disease, a useful trigger for proactive primary care? Mortality
9 7 results from a large UK cohort. *Fam Pract.* 2013;30(3):282-9.
10 8 27. James MT, et al. CKD and Risk of Hospitalization and Death With Pneumonia. *Am J Kidney Dis.*
11 9 2009;54(1):24-32.
12 10 28. Fried LF, et al. Kidney function as a predictor of noncardiovascular mortality. *J Am Soc*
13 11 *Nephrol.* 2005;16(12):3728-35.
14 12 29. Foley RN, Wang CC, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in
15 13 the US general population: The NHANES III study. *Mayo Clin Proc.* 2005;80(10):1270-7.
16 14 30. Mata-Cases M, et al. Is diabetes mellitus correctly registered and classified in primary care? A
17 15 population-based study in Catalonia, Spain. *Endocrinol Nutr.* 2016;63(9):440-8.
18 16 31. Smeets M, et al. Impact of an extended audit on identifying heart failure patients in general
19 17 practice: baseline results of the OSCAR-HF pilot study. *Esc Heart Fail.* 2020;7(6):3950-61.
20 18 32. Havas K, Douglas C, Bonner A. Meeting patients where they are: improving outcomes in early
21 19 chronic kidney disease with tailored self-management support (the CKD-SMS study). *Bmc Nephrol.*
22 20 2018;19.
23 21 33. Chen SH, et al. The impact of self-management support on the progression of chronic kidney
24 22 disease-a prospective randomized controlled trial. *Nephrol Dial Transplant.* 2011;26(11):3560-6.
25 23 34. Locatelli F, et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease.
26 24 *Nephrol Dial Transplant.* 2003;18:2-9.
27 25 35. Hamrahan SM, Falkner B. Hypertension in Chronic Kidney Disease. *Adv Exp Med Biol.*
28 26 2017;956:307-25.
29 27 36. World Health Organization. A global brief on hypertension: silent killer, global public health
30 28 crisis: World Health Day 2013. Geneva: 2013:1-39.
31 29 37. Xie X, et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in
32 30 Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. *Am J Kidney Dis.*
33 31 2016;67(5):728-41.
34 32 38. Ettehad D, et al. Blood pressure lowering for prevention of cardiovascular disease and death:
35 33 a systematic review and meta-analysis. *Lancet.* 2016;387(10022):957-67.
36 34 39. Fabbian F, et al. Evidence-based statin prescription for cardiovascular protection in renal
37 35 impairment. *Clin Exp Nephrol.* 2011;15(4):456-63.
38 36 40. Grundy SM, et al. Management of Blood Cholesterol. *J Am Col Cardiol.* 2019;73(24):E285-
39 37 U87.
40 38 41. Wright RS, et al. Acute myocardial infarction and renal dysfunction: A high-risk combination.
41 39 *Annof Intern Med.* 2002;137(7):563-70.
42 40 42. Shlipak MG, et al. Association of renal insufficiency with treatment and outcomes after
43 41 myocardial infarction in elderly patients. *Ann Intern Med.* 2002;137(7):555-62.
44 42 43. Muntner P, et al. Renal insufficiency and subsequent death resulting from cardiovascular
45 43 disease in the United States. *J Am Soc Nephrol.* 2002;13(3).
46 44 44. Sultan AA, et al. Inside CKD: modelling the economic burden of chronic kidney disease in
47 45 Europe using patient-level microsimulation. *Nephrol Dial Transplant.* 2021;36:306.
48 46 45. Ivers N, Jet al. Audit and feedback: effects on professional practice and healthcare outcomes.
49 47 *Cochrane Database Syst Rev.* 2012(6).
50 48 46. Van den Bulck S, et al. The effect of electronic audits and feedback in primary care and
51 49 factors that contribute to their effectiveness: a systematic review. *Int J Qual Health Care.*
52 50 2020;32(10):708-20.
53
54
55
56
57
58
59
60 51

1 **Table + table legend:**

Variable	Registered CKD, n(%)	Unregistered CKD, n(%)	Total CKD, n(%)	P-value
Total patients	3375	7176	10551	
All-cause mortality, n (%)	460(13.6)	820(11.4)	1280(12.1)	0.033
Myocardial Infarction, n (%)	28(0.8)	35(0.5)	63(0.6)	0.067
Stroke, n (%)	70(2.1)	113(1.6)	183(1.7)	0.089
Peripheral Vascular Disease, n (%)	52(1.5)	82(1.1)	134(1.3)	0.004
Heart Failure, n (%)	188(5.6)	308(4.3)	496(4.7)	0.001


2 **Table 1. Cardiovascular outcome associated with registration status.**

3

4

1 **Figures + figure legends:**

2




3

	Number at risk					
	0	1	2	3	4	5
Registered CKD, stage 3A	1679	1608	1406	1085	640	77
Registered CKD, stage 3B	1210	1157	1021	831	585	117
Registered CKD, stage 4	387	358	308	245	170	46
Registered CKD, stage 5	99	87	70	51	33	14
Unregistered CKD, stage 3A	5699	5386	4601	3213	1604	155
Unregistered CKD, stage 3B	1221	1086	925	704	393	46
Unregistered CKD, stage 4	210	170	137	99	64	18
Unregistered CKD, stage 5	46	35	31	23	16	4
	0	1	2	3	4	5
	Time (years)					

4

5 **Figure 1. Strata analysis for mortality.** Survival probability in different years grouped by CKD stage and
 6 presence of diagnostic code. Risk set table with number of patients at risk per year.



Number at risk

Registered CKD, stage 3A	1679	1656	1500	1186	723	89
Registered CKD, stage 3B	1210	1192	1105	936	678	150
Registered CKD, stage 4	387	384	360	310	231	74
Registered CKD, stage 5	99	98	90	75	60	25
Unregistered CKD, stage 3A	5699	5631	4971	3593	1840	190
Unregistered CKD, stage 3B	1221	1192	1088	894	558	73
Unregistered CKD, stage 4	210	208	187	149	111	29
Unregistered CKD, stage 5	46	44	41	35	27	9
	0	1	2	3	4	5

Time (years)

Figure 2. Strata analysis for cardiovascular disease. Morbidity probability in different years grouped by CKD stage and presence of diagnostic code. Risk set table with number of patients at risk per year.





Figure 3. Mortality and time to event. HRs and the 95% confidence interval (95% CI) for different variables.

Systolic blood pressure (SBP), Body Mass Index (BMI), cardiovascular disease (CVD)

1




2

3 **Figure 4. Cardiovascular disease with mortality as a competing risk.** sHRs and the 95% confidence interval
 4 (95% CI) for different variables.


5 Systolic blood pressure (SBP), Body Mass Index (BMI), cardiovascular disease (CVD)

6



	Number at risk					
	0	1	2	3	4	5
Registered CKD, stage 3A	1679	1608	1406	1085	640	77
Registered CKD, stage 3B	1210	1157	1021	831	585	117
Registered CKD, stage 4	387	358	308	245	170	46
Registered CKD, stage 5	99	87	70	51	33	14
Unregistered CKD, stage 3A	5699	5386	4601	3213	1604	155
Unregistered CKD, stage 3B	1221	1086	925	704	393	46
Unregistered CKD, stage 4	210	170	137	99	64	18
Unregistered CKD, stage 5	46	35	31	23	16	4
	0	1	2	3	4	5

Figure 1. Strata analysis for mortality. Survival probability in different years grouped by CKD stage and presence of diagnostic code. Risk set table with number of patients at risk per year.



	Number at risk					
	0	1	2	3	4	5
Registered CKD, stage 3A	1679	1656	1500	1186	723	89
Registered CKD, stage 3B	1210	1192	1105	936	678	150
Registered CKD, stage 4	387	384	360	310	231	74
Registered CKD, stage 5	99	98	90	75	60	25
Unregistered CKD, stage 3A	5699	5631	4971	3593	1840	190
Unregistered CKD, stage 3B	1221	1192	1088	894	558	73
Unregistered CKD, stage 4	210	208	187	149	111	29
Unregistered CKD, stage 5	46	44	41	35	27	9
	0	1	2	3	4	5
	Time (years)					

Figure 2. Strata analysis for cardiovascular disease. Morbidity probability in different years grouped by CKD stage and presence of diagnostic code. Risk set table with number of patients at risk per year.




Figure 3. Mortality and time to event. HRs and the 95% confidence interval (95% CI) for different variables. Systolic blood pressure (SBP), Body Mass Index (BMI), cardiovascular disease (CVD)




Figure 4. Cardiovascular disease with mortality as a competing risk. sHRs and the 95% confidence interval (95% CI) for different variables.

Systolic blood pressure (SBP), Body Mass Index (BMI), cardiovascular disease (CVD)

Variable	Registered CKD, n(%)	Unregistered CKD, n(%)	Total CKD, n(%)	P-value
Total patients	3375	7176	10551	
All-cause mortality, n (%)	460(13.6)	820(11.4)	1280(12.1)	0.033
Myocardial Infarction, n (%)	28(0.8)	35(0.5)	63(0.6)	0.067
Stroke, n (%)	70(2.1)	113(1.6)	183(1.7)	0.089
Peripheral Vascular Disease, n (%)	52(1.5)	82(1.1)	134(1.3)	0.004
Heart Failure, n (%)	188(5.6)	308(4.3)	496(4.7)	0.001

Table 1. Cardiovascular outcome associated with registration status.

Additional file 1: ATC codes

Antihypertensiva

- ACE inhibitors: C09A, C09B, or C10BX04, C10BX06, C10BX07, C10BX11, C10BX12, C10BX13, C10BX14, C10BX15, C10BX17, C10BX18 (combination)
- ARBs: C09C, C09D, or C10BX10, C10BX16 (combination)
- Angiotensin receptor-neprilysin inhibitor (ARNI): C09DX04
- Beta blockers: C07
- Calcium channel blockers: C08C, C08D, C08G, or C10BX03, C10BX07, C10BX09, C10BX11, C10BX14, C10BX18
- Alpha blockers, i.e., clonidine, moxonidine and methyldopa: C02AC01, C02AC05, C02AB
- Thiazide diuretics: C03A, or C10BX13
- Aldosterone receptor agonists (MRA): C03DA
- Loop diuretics: C03C

Lipid lowering medication

- C10

Antidiabetic drugs


- Metformin: A10BA02, or A10BD02, A10BD03, A10BD05, A10BD07, A10BD08, A10BD10, A10BD11, A10BD13, A10BD14, A10BD15, A10BD16, A10BD17, A10BD18, A10BD20, A10BD22, A10BD23, A10BD25, A10BD26 (combination)
- Sulphonylurea: A10BB, or A10BD01, A10BD02, A10BD04, A10BD06 (combination)
- Dipeptidyl peptidase 4 inhibitors (DPP-4i): A10BH, or A10BD07, A10BD08, A10BD09, A10BD10, A10BD11, A10BD12, A10BD13 (combination)
- Glucagon-like peptide-1 receptor agonist (GLP1-RA): A10BJ
- Insulin: A10AB, A10AC, A10AD, A10AE
- SGLT2s: A10BK01, A10BK02, A10BK03, A10BK04 or A10BD15, A10BD16, A10BD19, A10BD20, A10BD21, A10BD23, A10BD24, A10BD25 (in combination)
- Other oral anti-diabetic (OADs); Pioglitazon, acarbose, repaglinide: A10BG03, A10BF01, A10BX02, or A10BD05, A10BD06, A10BD12, A10BD14, A10BD17 (combination)

Additional file 2: Missing variables

Variable	Missingness
Total patients	10551
Smoking	75.98%
SBP	7.89%
Total Cholesterol	15.2%
BMI	55.34%

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5
		(b) For matched studies, give matching criteria and number of exposed and unexposed	/
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	5-7
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	7
		(d) If applicable, explain how loss to follow-up was addressed	Not applicable
		(e) Describe any sensitivity analyses	Not applicable
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	Additional file 2
		(c) Summarise follow-up time (eg, average and total amount)	8
Outcome data	15*	Report numbers of outcome events or summary measures over time	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8-9
		(b) Report category boundaries when continuous variables were categorized	Not applicable
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8-9
Discussion			
Key results	18	Summarise key results with reference to study objectives	10
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Association between non-registration of chronic kidney disease and mortality and cardiovascular outcome: a time-to-event analysis of retrospective primary care data

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-081115.R1
Article Type:	Original research
Date Submitted by the Author:	29-Mar-2024
Complete List of Authors:	Van den Wyngaert, Ine; KU Leuven, Department of Public Health and Primary Care Mamouris, Pavlos; KU Leuven, Department of Public Health and Primary Care Ali, Endale Alemayehu; KU Leuven, Department of Public Health and Primary Care Vaes, Bert; KU Leuven, Departement of Public Health and Primary Care Van Pottelbergh, Gijs; KU Leuven, Department of Public Health and Primary Care
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	Cardiovascular medicine, General practice / Family practice, Renal medicine
Keywords:	Chronic renal failure < NEPHROLOGY, Mortality, CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1 **Association between non-registration of chronic kidney disease and mortality and**
4 2 **cardiovascular outcome: a time-to-event analysis of retrospective primary care data**
5
6
7 3

8
9 4 Ine Van den Wyngaert*¹, Pavlos Mamouris¹, Endale Alemayehu Ali¹, Bert Vaes¹ and Gijs Van
10 5 Pottelbergh¹
11
12
13 6

14
15 7 ¹Academic Centre for General Practice, Department of Public Health and Primary Care, University of
16 8 Leuven, Leuven, Belgium.
17
18
19 9

20
21 10 *Correspondence to:
22

23 11 Ine Van den Wyngaert

24
25 12 E-mail: ine.vandenwyngaert@kuleuven.be
26
27 13

28
29 14 **Keywords:** cardiovascular, chronic renal failure, mortality, survival analysis, non-registration
30
31 15

32
33 16 **Word count:** 3188
34

35 17 **Number of figures, tables, boxes, references:** 4 figures, 1 table, 47 references
36
37 18

38
39 19 **Abstract**

40
41 20 **Objective**

42
43 21 Patients with impaired kidney function and increased albuminuria are at risk of developing
44 22 cardiovascular disease. Previous research has revealed that a substantial proportion of patients with
45 23 chronic kidney disease do not get a registered diagnosis in the electronic health record of the general
46 24 practitioner. The aim of this study was to investigate the association between non-registration of
47 25 chronic kidney disease and all-cause mortality and cardiovascular outcome.
48
49
50
51

52 26 **Design and setting**

53
54
55 27 A retrospective study in primary care.
56

57 28 **Methods**

58
59 29 The analyses were carried out in the INTEGO database, a general practice-based morbidity
60 30 registration network in Flanders, Belgium. The study used INTEGO data from the year 2018 for all

1
2
3 31 patients ≥ 18 years old, including 10551 patients. To assess the risk of mortality and cardiovascular
4 32 disease, a time-to-event analysis was performed. Cox proportional hazard model was used to
5 33 evaluate the association between non-registration and incidence of all-cause mortality and
6 34 cardiovascular events with mortality as a competing risk. Subgroup analyses were performed for
7 35 estimated glomerular filtration rate stages (3a, 3b, 4 and 5). Multiple imputation was done following
8 36 the methodology of Mamouris et al.

37 **Results**

38 Mortality was higher in patients with non-registered chronic kidney disease compared to patients
39 with registered CKD (HR 1.29, 95% CI 1.19-1.41). Non-registration of chronic kidney disease was not
40 associated with an increased risk for the development of cardiovascular disease (HR 0.92, 95% CI
41 0.77-1.11).

42 **Conclusion**

43 An association between non-registration and all-cause mortality was identified, although no such
44 association was apparent for cardiovascular disease.

1
2
3 45 **Strengths and limitations of this study**
4

- 5
6 46 - To assess the risk of CVD and mortality, Cox-proportional hazard models were used and a
7 47 competing risk analysis was performed to account for the presence of competing event
8 (mortality).
9 48
10 49 - For the missing variables, we used multiple imputation.
11
12 50 - The presence of proteinuria was not taken into account in our CKD population due to the lack
13 of data.
14 51
15 52 - The study used healthcare data, which may underrepresent the healthy and asymptomatic
16 that do not seek healthcare.
17 53
18 54 - The participating GPs are a selected group of high quality registering practitioners that use a
19 specific electronic health record, although the patient population is representative for the
20 Flemish population.
21 55
22 56
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

57 INTRODUCTION

58 Chronic kidney disease (CKD) is a progressive condition that describes the gradual loss of kidney
59 function over time. A reduced estimated glomerular filtration rate (eGFR) and elevated albuminuria
60 are the two key measures in patients with CKD [1]. Multiple studies have documented suboptimal
61 albuminuria testing in CKD patients in primary care [2, 3]. However, both reduced eGFR and the
62 presence of albuminuria are associated with an increased risk of cardiovascular disease (CVD),
63 hospitalisation and premature death [4-9]. The most common causes of CKD in high-income and
64 middle-income countries are glomerulonephritis, diabetes mellitus and hypertension (the latter being
65 also a consequence of CKD) [10-12]. The increased cardiovascular risk (CVR) in patients with CKD was
66 therefore assumed to be the result of these underlying diseases. However, meta-analyses showed that
67 impaired kidney function and increased albuminuria are CVR factors, independently of the presence
68 of hypertension or diabetes mellitus [6, 13]. Kidney specific mechanisms that make significant
69 contributions to the CVR were documented [4].

70 Previous research revealed that a substantial proportion of patients did not have a registered CKD
71 diagnosis in the general practitioner's (GP) electronic health record (EHR) [14, 15]. In addition, mainly
72 patients with early-stage CKD (stage 3) remained without official diagnosis [15]. Although we know
73 that patients with CKD are more at risk, the impact of not registering a diagnosis has not been
74 investigated, neither on cardiovascular outcome nor on mortality [4-6].

75 The aim of this study was to evaluate the impact of non-registration on all-cause mortality and
76 cardiovascular outcome in Flanders, Belgium.

77 **METHODS**

78 **Study setting and data source**

79 This study was conducted following on from previous work [15]. In that research, the prevalence of
80 non-registered CKD, the diagnostic delay (time between abnormal eGFR and diagnosis) and the
81 baseline characteristics of the non-registered patient group were examined in a Belgian GP population.
82 The same study population was used.

83 The analyses were carried out in the INTEGO database, a general practice-based computerised
84 morbidity and mortality registration network in Flanders, Belgium, managed at the Department of
85 General Practice of the University of Leuven since 1994. Data collection is regulated by an opting-out
86 procedure. INTEGO procedures were approved by the ethical review board of the Medical School of
87 KU Leuven (N° ML 1723) and by the Belgian Privacy Commission (no SCSZG/13/079). More than 100
88 GP centres applied for inclusion in this registry. Only the data of the 86 practices (representing 454
89 GPs) with optimal registration performance (80% coded diagnoses) were included in the database.
90 Patient characteristics and diagnoses are encoded and classified using the International Classification
91 of Primary Care (ICPC-2; WHO FIC Collaborating Centre). All laboratory tests performed by GPs are
92 included in the database.

93 The methodology of data collection, study design, and analyses in the INTEGO registry have been
94 previously reported [16].

95 **Study population**

96 Guidelines for CKD management recommend that patients should be diagnosed with CKD if the
97 reduction in kidney function (eGFR <60 mL/ min/1.73 m²) is present for more than three months [1,
98 17, 18]. All patients ≥18 years old with two consecutive eGFR laboratory measurements indicating
99 CKD (eGFR <60 mL/min/1.73m²) recorded >90 and ≤730 days apart during the baseline period were
100 included. The current study used INTEGO data from the year 2018. Selected patients had at least one
101 eGFR measurement <60 mL/min/1.73m² in 2018 and belonged to the GP's yearly contact group. There
102 must be at least 12 months of continuous presence in the database prior to the first qualifying eGFR.
103 Patients were excluded if they had a solid kidney transplant (ICD-10 Z94.0) before the date of the
104 second qualifying eGFR (index date).

105 **Non-registered CKD case definition**

106 Patients with Non-registered CKD were identified if they had no diagnostic CKD code for any time
107 during the ≥12-month lookback period before the first eGFR measurement and up to 6 months post-
108 index date. ICPC-2 codes are used more frequently in general practice than ICD-10, so we chose to

1
2
3 109 use the ICD-10 code U99. Those with a documented U99 during this time period were considered as
4
5 110 having registered CKD. Since the U99 code is a collective code for unspecified kidney disease - like
6
7 111 chronic kidney disease, renal cyst - we manually checked both the code and the written diagnosis
8
9 112 whether the code did merge with CKD. It was assumed that patients with at least one diagnostic code
10
11 113 for CKD during the above specified time window had registered CKD.

12 114 **Statistical analysis**

14 115 R software (version 4.0.4) was used [19]. A descriptive analysis was performed, calculating incidences
15
16 116 of all-cause mortality, myocardial infarction, stroke, peripheral vascular disease and heart failure
17
18 117 among those with registered versus Non-registered CKD. The follow-up period for these adverse
19
20 118 clinical outcomes started six months after the index date until observation end date (follow-up end
21
22 119 date or end of data coverage up to 17/07/2023, whichever came first). The variables were
23
24 120 summarised using patient counts with percentages. The chi-square was calculated. P values less than
25
26 121 0.05 were considered significant. Subgroup analyses were performed for eGFR stages (3a, 3b, 4 and
27
28 122 5) and visualised using Kaplan-Meier curves.

29 123 To assess the risk of CVD and mortality, Cox-proportional hazard model was used. A competing risk
30
31 124 analysis was performed to account for the presence of competing event (mortality) [20]. We
32
33 125 estimated the hazard ratios (HRs) and derived the sub-distribution hazard ratios (sHRs) from the Fine
34
35 126 and Gray model. Their 95% confidence interval (CI) was calculated. P values less than 0.05 were
36
37 127 considered significant. We adjusted for all possible confounders (age, gender, hypertension,
38
39 128 diabetes, smoking status, hypercholesterolemia, history of CVD). We fitted the models by including
40
41 129 and excluding covariates one-by-one (sequential method) and we did not find significant change
42
43 130 in the estimate and significance of covariates which were already in the model after adding new
44
45 131 covariate. We calculated the Variance Inflation Factor to check for multicollinearity [21].

46 132 Variables were chosen based on the risk factors for CVD, defined by the Framingham Heart Study
47
48 133 [22]. Cardiovascular events were defined as myocardial infarction (ICPC-2 K75), stroke (ICPC-2 K90),
49
50 134 peripheral vascular disease (ICPC-2 K92) and heart failure (ICPC-2 K77). Hypertension or
51
52 135 hypercholesterolemia included patients with a diagnosis of hypertension (ICPC-2 K86) or
53
54 136 hypercholesterolemia (ICPC-2 T93) in the EHR. Antihypertensive, lipid lowering and antidiabetic
55
56 137 medication were defined by the ATC-codes (Supplemental file 1). Patients with a diagnosis of
57
58 138 diabetes type 1 or 2 in the EHR (ICPC-2 T89 and T90) and patients taking antidiabetic drugs were
59
60 139 merged into the diabetes group. Since there was multicollinearity between total cholesterol, HDL and
140
141 LDL, we chose to include total cholesterol.

1
2
3 142 For the missing variables, we used the methodology developed by Mamouris et al [23]. Concisely, in
4
5 143 their work, they developed a 3-stage approach to impute longitudinal covariates so as complexities
6
7 144 such as convergence and collinearity are resolved [23]. We imputed Body Mass Index (BMI), total
8
9 145 cholesterol, systolic blood pressure (SBP) and smoking status longitudinally for years 2017-2023, thus
10
11 146 utilising the previous and earlier information of the same patient (Supplemental file 2). We then
12
13 147 extracted the observed year 2018. The dataset was imputed 20 times and model analysis was
14
15 148 performed for each imputation separately. We finally pooled the results together using Rubin's rules
16
17 149 [24].
18
19 150

151 **Patient and public involvement**

20
21 152 None.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

153 RESULTS

154 As reported in our first research, 231 702 patients ≥ 18 years old were detected in the INTEGO database
 155 in 2018 (Supplemental file 3). The maximum follow-up was 3.97 years. Since the general practice didn't
 156 meet the criteria for best quality register, 40 216 patients were excluded. Among included patients,
 157 there were 10 551 patients (5.5%) with two consecutive eGFR laboratory measurements indicating
 158 chronic kidney disease (CKD) (eGFR < 60 mL/min/1.73m²), recorded at least three months apart during
 159 the baseline period. Out of them, 7176 patients (68%) had no U99 at any time. The other 3375 patients
 160 (32%) had a registered diagnosis [15].

161 Descriptive analysis

162 *Incidences*

163 Incidences of all-cause mortality, myocardial infarction, stroke, peripheral vascular disease and heart
 164 failure associated with CKD diagnosis status as of index date, are being displayed in Table 1.

Variable	Registered CKD, n (%)	Non-registered CKD, n (%)	Total CKD, n (%)	P-value
Total patients	3375	7176	10551	
All-cause mortality, n (%)	460(13.6)	820(11.4)	1280(12.1)	0.033
Myocardial Infarction, n (%)	28(0.8)	35(0.5)	63(0.6)	0.067
Stroke, n (%)	70(2.1)	113(1.6)	183(1.7)	0.089
Peripheral Vascular Disease, n (%)	52(1.5)	82(1.1)	134(1.3)	0.004
Heart Failure, n (%)	188(5.6)	308(4.3)	496(4.7)	0.001

166 **Table 1. Cardiovascular outcome associated with registration status**

167

168 *Strata analyses*

169 Figures 1 and 2, respectively, display the differences in survival time and time to development of CVD
 170 in patients with CKD, according to the CKD stage and presence of diagnostic code in the EHR. An
 171 informative risk set table shows the number of patients who were under observation and at risk in the
 172 specific period. It appeared that registered patients in stage 3B and 4 had a much better survival rate
 173 than non-registered patients after 3 years of follow-up, namely 82.23% (registered group, stage 3B)
 174 and 72.87% (registered group, stage 4) towards 73.05% (non-registered group, stage 3B) and 59.52%
 175 (non-registered group, stage 4) (Figure 1). The same difference was documented for CKD stage 5 after
 176 1 year of follow-up. In the registered group, 87.88% survived at that time, towards 76.09% of the non-

1
2
3 177 registered patients. Only a small number of stage 5 patients were still under observation after 3 years
4
5 178 of follow-up, making it difficult to interpret the results at that time (Figure 1). Similar survival curves
6
7 179 were reported in both registered and non-registered in stage 3A.

8
9 180 Similar to the findings for mortality, less registered patients in stage 5 developed CVD compared to
10
11 181 non-registered stage 5 patients after 1 year of follow-up (morbidity rate 98.99% in the registered
12
13 182 group, towards 95.65% in the non-registered group) (Figure 2). In stage 3B and 4 were the differences
14
15 183 in morbidity rate between registered and non-registered smaller after 3 years of follow-up compared
16
17 184 to what we documented for mortality, respectively 93.80% (registered, stage 3B and 4) compared to
18
19 185 93.28% (non-registered, stage 3B) and 95.24% (non-registered, stage 4). As for mortality, stage 3A
20
21 186 showed similar results curves for non-registered and registered.

21 187 Time to event-analysis

22
23 188 Figures 3 and 4, respectively, show the time to the occurrence of death or CVD with mortality as a
24
25 189 competing risk. Results for analyses with and without mortality as a competing risk were similar.

26
27 190 All-cause mortality analysis showed that patients with non-registered CKD, male gender, age ≥ 65 ,
28
29 191 diabetes, CKD stage 3B-5, history of CVD and (ex-)smokers had a higher chance of dying. Hypertension
30
31 192 and hypercholesterolemia were protective factors, as was the use of antihypertensive and lipid
32
33 193 lowering medication and BMI. The values for smoking and hypercholesterolemia were not statistically
34
35 194 significant. The HR for total cholesterol was equal to 1.

36
37 195 Considering the results for CVD, only age ≥ 65 , hypertension, antihypertensive medication, CKD stage
38
39 196 3B, BMI, total cholesterol and history of CVD were statistically significant. The sub-distribution hazard
40
41 197 ratio (sHR) for non-registered CKD was < 1 . A history of CVD and hypercholesterolemia seemed to be
42
43 198 protective factors for CVD, while patients with hypertension had an increased risk.

199 **DISCUSSION**

200 **Principal findings**

201 This study showed that patients with a properly registered diagnosis die less quickly than non-
202 registered ones. However, according to our results, these patients did not appear to have a lower risk
203 to develop CVD. Besides, patients in stage 3B and 4 with a registered diagnosis had much better
204 mortality survival rates compared to the non-registered ones. The association of non-registration and
205 CVD was less clear in the different CKD stages.

206 Patients with CKD and hypercholesterolemia showed to be less associated with CVD and mortality,
207 although the result was not statistically significant. In contrast, hypertensive CKD patients appeared to
208 have a higher risk of CVD, but a lower risk of mortality. Patients with a history of CVD seemed to have
209 a lower risk of new events, but a higher risk to die.

210 **Context of the results**

211 Non-registration appears to be associated with all-cause mortality. However, the CaReMe CKD study
212 recently showed that the rates of cardiovascular and all-cause death were 31-49% higher in registered
213 CKD patients than in measured CKD patients, which could not be confirmed in our study [25]. Few
214 research has been conducted in this regard, making it difficult to compare. We must note that non-
215 registration may be a risk factor to mortality comparable to diabetes, but outweighed by age and stage
216 of CKD by far. An association was found, but causality was not investigated. It is unclear whether better
217 registration will lead to a better outcome, so this should be a topic for further research.

218 The key research question of our results is what caused patients to die. Previous research showed that
219 a reduced kidney function predicts both cardiovascular and non-cardiovascular mortality due to
220 pulmonary disease, infection, cancer, and other causes [26-28]. The association between a reduced
221 eGFR and the increased risk of cardiovascular events and hospitalisation was also found [9, 12, 29].
222 Surprisingly, the non-registered group in our study did not have a higher risk of CVD than the
223 registered. It is unclear why no association was found. Possibly, this group died more frequently as a
224 result of non-CVD. On the other hand, non-registration probably extends beyond renal insufficiency
225 and also occurs with other pathologies. Mata-Casas et al. reported non-registration of diabetes
226 mellitus in Spanish primary health care [30]. Cardiovascular diagnosis may also be non-registered, so
227 that no association with non-registration could be found [31].

228 A second important question remains why the difference in mortality outcome was found between
229 registered and non-registered patients. Is the root of the problem with the GP or the patient? Our
230 previous research showed that there were small differences between registered and non-registered

1
2
3 231 patients at baseline [15]. Hypertension was more frequently present in the registered (64.4% of the
4
5 232 registered population) compared to the non-registered (51.7% of the non-registered population).
6
7 233 Similar results were found for type 2 diabetes (33.1% of the registered compared to 28.2% of the non-
8
9 234 registered). Small differences were also noticeable in the use of ACE-I or ARB (52.6% among the
10
11 235 registered compared to 46.3% of the non-registered) [15]. However, these small differences do not
12
13 236 seem to provide an adequate explanation for the difference in mortality, partly in view of the result
14
15 237 that the non-registered group had no higher risk of CVD.

16
17 238 Subsequently, the follow-up of these patients should be assessed. A possible explanation for the
18
19 239 difference in mortality between registered and non-registered groups could be that less attention was
20
21 240 paid while prescribing and dispensing nephrotoxic (over-the-counter) medication by the GP and
22
23 241 pharmacist, resulting in further deterioration of kidney function. There may have been less attention
24
25 242 to the CVR factors associated with impaired renal function. In that case, we also would have expected
26
27 243 an increase in CVD, unless, as previous described, it concerns a problem of global non-registration. On
28
29 244 the other hand, the responsibility of the patient in the follow-up of the disease must be brought to
30
31 245 attention. Possibly, the non-registered group contained a large proportion of patients who were not
32
33 246 adherent to follow-up and therapy, as a result of which some did not or belatedly encountered
34
35 247 problems. So, it is becoming increasingly important to examine these hypotheses and to involve the
36
37 248 patient in his care and to find out what view he has in this regard [32, 33]. Moreover, it seems useful
38
39 249 to investigate why the diagnosis was not registered in the EHR. Based on these results, the problem of
40
41 250 non-registration could be addressed.

42
43 251 According to our research results, hypertension in CKD patients would be a risk factor in the
44
45 252 development of CVD, although a protective factor in the development of all-cause mortality. Though,
46
47 253 we know from previous research that hypertension is a risk factor for the development of CVD and
48
49 254 premature death [34-36]. The reasons for this difference are unclear. We need to consider the effect
50
51 255 of antihypertensive medication on this outcome, since 48% of the patients took an Angiotensin-
52
53 256 converting-enzyme-inhibitor (ACE-I) or an Angiotensin Receptor Blocker (ARB) [15]. The beneficial
54
55 257 effect of these drugs on cardiovascular events and all-cause mortality has been confirmed in the past
56
57 258 [37]. Ettehad et al. described that in patients with CKD smaller risk reductions in cardiovascular events
58
59 259 were seen as a result of antihypertensive medication than in patients without CKD [38]. However, we
60
61 260 should also keep in mind that there may be non-registration of hypertension and SBP.

62
63 261 Additionally, it is surprising that hypercholesterolemia and total cholesterol do not show a higher risk
64
65 262 on CVD and mortality, since this is a proven risk factor for CVD [22, 39]. De Nicola et al. showed that
66
67 263 the cardiovascular risk increases linearly with higher LDL in non-dialysis CKD patients [39]. However,
68
69 264 this result was not significant and may be explained by the use of lipid lowering medication, as 45% of

1
2
3 265 patients were on this medication at baseline [15]. After all, Fabbian F. et al. determined that statins
4 266 are an effective treatment in CKD patients, especially in the early stages of the disease [40]. A history
5 267 of CVD appears to be a protective factor in the development of new CVD, of which a properly adjusted
6 268 therapy can be the reason (secondary prevention) [40, 41]. In addition, we know that CKD is associated
7
8 269 with adverse outcomes in those with existing CVD, which includes increased mortality after an acute
9
10 270 coronary syndrome [42-44].

11
12
13
14 271 In our previous work, we found that the majority of patients with renal insufficiency were in stage 3,
15 272 with a higher proportion registered in stage 5 (75.7% registered) compared to stage 3a (22.9%
16 273 registered) [15]. However, this study showed major differences in survival rates between registered
17 274 and non-registered patients in both the earlier (3B) and further stages (4 and 5) of renal failure. The
18 275 importance of early detection has been described many times in the past [17, 45]. This research must
19 276 therefore be a plea for early detection of CKD and registration of the diagnostic code in the EHR. Good
20 277 mutual communication between GP and nephrologist through referral letters and clear consultation
21 278 reports can contribute to this. A solution to detect non-registered patients can be found in an Audit-&
22 279 Feedback system, since this has proven to be effective and to have added value in primary care [46,
23 280 47].

31 **Limitations**

32
33 282 There were some limitations to note. First, we did not take the presence of proteinuria into account in
34 283 our CKD population. Mainly due to the lack of data on proteinuria, which brings us straight to the
35 284 problem of non-detection of proteinuria in the Flemish general practice.

36
37
38
39 285 Subsequently, the study used healthcare data which may underrepresent the healthy and
40 286 asymptomatic that do not seek healthcare. The data of care refusers were included in the research
41 287 results.

42
43
44
45 288 Although the patient population is representative for the Flemish population, registering GPs are not
46 289 representative for the GP population. It is a selected group of high quality registering practitioners that
47 290 use a specific electronic health record. This selection bias of GPs could eventually have an influence on
48 291 some process parameters in the follow-up of patients [16]. In addition, data collected in a real-world
49 292 setting may lack information on specific covariates and laboratory investigations. Lab results from the
50 293 hospital and specialists are automatically entered into the EHR, but their diagnoses are not. The large
51 294 proportion of missingness is a limitation as well. We used multiple imputation to fill in this missingness
52 295 (see method section).

53
54
55
56
57
58
59 296
60

1
2
3 297 **CONCLUSION**
4

5
6 298 An association between non-registration and all-cause mortality was identified, although no such
7
8 299 association was apparent for CVD. Patients in stage 3B and 4 CKD with a registered diagnosis had much
9
10 300 better survival rates compared with non-registered patients. It is unclear whether better registration
11
12 301 will lead to a better outcome; the differences between these patient groups must be further mapped
13
14 302 out.
15

16 303
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 304 **Data availability statement:** All relevant data are included in this published article (and its
4 supplemental files), except for the data underlying Figures 1-4. As this data contains individual patient
5 305 records, it can only be accessed inside a monitored analysis environment. Access to the data
6 306 environment will be given to individual researchers on reasonable request.
7
8
9

10 308 **Funding:** This research received no specific grant from any funding agency in the public, commercial
11 or not-for-profit sectors.
12
13

14 310 **Contributors:** IVDW, PM, BV and GVP designed and conceptualized the study. EAA and PM performed
15 the data analysis. IVDW drafted the manuscript. IVDW, EAA, PM, BV and GVP revised the manuscript.
16 311 IVDW and GVP are the guarantors of this work. All authors read and approved the final manuscript.
17
18
19

20 313 **Competing interests:** None declared.
21
22

23 314 **Ethics approval:** This study involves human participants. INTEGO procedures were approved by the
24 ethical review board of the Medical School of KU Leuven (N° ML 1723) and by the Belgian Privacy
25 315 Commission (no SCSZG/13/079).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

317 **References**

- 318 1. Levin A, et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO
319 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney*
320 *Int Suppl.* 2013;3(1):1-150.
- 321 2. Stevens PE, et al. Chronic kidney disease management in the United Kingdom: NEOERICA
322 project results. *Kidney Int.* 2007;72(1):92-9.
- 323 3. Allen AS, et al. Primary Care Management of Chronic Kidney Disease. *J Gen Intern Med.*
324 2011;26(4):386-92.
- 325 4. Gansevoort RT, et al. Chronic kidney disease and cardiovascular risk: epidemiology,
326 mechanisms, and prevention. *Lancet.* 2013;382(9889):339-52.
- 327 5. Matsushita K, et al. Association of estimated glomerular filtration rate and albuminuria with
328 all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.
329 *Lancet.* 2010;375(9731):2073-81.
- 330 6. Mahmoodi BK, et al. Associations of kidney disease measures with mortality and end-stage
331 renal disease in individuals with and without hypertension: a meta-analysis. *Lancet.*
332 2012;380(9854):1649-61.
- 333 7. Thompson S, et al. Cause of Death in Patients with Reduced Kidney Function. *J Am Soc*
334 *Nephrol.* 2015;26(10):2504-11.
- 335 8. Muntner P, et al. History of myocardial infarction and stroke among incident end-stage renal
336 disease cases and population-based controls: An analysis of shared risk factors. *Am J Kidney Dis.*
337 2002;40(2):323-30.
- 338 9. Go AS, et al. Chronic kidney disease and the risks of death, cardiovascular events, and
339 hospitalization. *N Engl J Med.* 2004;351(13):1296-305.
- 340 10. De Bhailis AM, Kalra PA. Hypertension and the kidneys. *Br J Hosp Med (Lond).* 2022;83(5).
- 341 11. Xie Y, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and
342 national trends of chronic kidney disease epidemiology from 1990 to 2016. *Kidney Int.*
343 2018;94(3):567-81.
- 344 12. Webster AC, et al. Chronic kidney disease. *Lancet.* 2017;389(10075):1238-52.
- 345 13. Fox CS, et al. Associations of kidney disease measures with mortality and end-stage renal
346 disease in individuals with and without diabetes: a meta-analysis. *Lancet.* 2012;380(9854):1662-73.
- 347 14. Ryan TP, et al. Chronic kidney disease prevalence and rate of diagnosis. *Am J Med.*
348 2007;120(11):981-6.
- 349 15. Van den Wyngaert I, et al. An exploration of under-registration of chronic kidney disease in
350 Belgian general practices using logistic regression. *Plos One.* 2022;17(12):e0279291.
- 351 16. Truyers C, et al. The Intego database: background, methods and basic results of a Flemish
352 general practice-based continuous morbidity registration project. *Bmc Med Inform Decis Mak.*
353 2014;14:48.
- 354 17. Shlipak MG, et al. The case for early identification and intervention of chronic kidney disease:
355 conclusions from a Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference.
356 *Kidney Int.* 2021;99(1):34-47.
- 357 18. Van Pottelbergh G, et al. Richtlijn voor goede medische praktijkvoering: Chronische
358 nierinsufficiëntie. *Domus Medica.* 2012.
- 359 19. Team R. R: A Language and Environment for Statistical Computing. Vienna, Austria: R
360 Foundation for Statistical Computing, 2021.
- 361 20. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians.
362 *Bone Marrow Transplant.* 2007;40(4):381-7.
- 363 21. Tsagris M, Pandis N. Multicollinearity. *Am J Orthod Dentofacial Orthop.* 2021;159(5):695-6.
- 364 22. D'Agostino RB, et al. General cardiovascular risk profile for use in primary care: The
365 Framingham heart study. *Circulation.* 2008;117(6):743-53.
- 366 23. Mamouris P. A longitudinal transition imputation model for categorical data applied to a
367 large registry dataset. *Statistics in medicine.* 2023, In press.

- 1
2
3 368 24. Rubin DB, Campion WM. Multiple imputation for nonresponse in surveys. *J Mark Res.* 1989;26(4):485-6.
4 369
5 370 25. Sundström J, et al. Prevalence, outcomes, and cost of chronic kidney disease in a
6 371 contemporary population of 2,4 million patients from 11 countries: The CaReMe CKD study. *Lancet*
7 372 *Reg Health Eur.* 2022;20:100438.
8 373 26. Marks A, et al. Chronic kidney disease, a useful trigger for proactive primary care? Mortality
9 374 results from a large UK cohort. *Fam Pract.* 2013;30(3):282-9.
10 375 27. James MT, et al. CKD and Risk of Hospitalization and Death With Pneumonia. *Am J Kidney Dis.*
11 376 2009;54(1):24-32.
12 377 28. Fried LF, et al. Kidney function as a predictor of noncardiovascular mortality. *J Am Soc*
13 378 *Nephrol.* 2005;16(12):3728-35.
14 379 29. Foley RN, Wang CC, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in
15 380 the US general population: The NHANES III study. *Mayo Clin Proc.* 2005;80(10):1270-7.
16 381 30. Mata-Cases M, et al. Is diabetes mellitus correctly registered and classified in primary care? A
17 382 population-based study in Catalonia, Spain. *Endocrinol Nutr.* 2016;63(9):440-8.
18 383 31. Smeets M, et al. Impact of an extended audit on identifying heart failure patients in general
19 384 practice: baseline results of the OSCAR-HF pilot study. *Esc Heart Fail.* 2020;7(6):3950-61.
20 385 32. Havas K, Douglas C, Bonner A. Meeting patients where they are: improving outcomes in early
21 386 chronic kidney disease with tailored self-management support (the CKD-SMS study). *Bmc Nephrol.*
22 387 2018;19.
23 388 33. Chen SH, et al. The impact of self-management support on the progression of chronic kidney
24 389 disease-a prospective randomized controlled trial. *Nephrol Dial Transplant.* 2011;26(11):3560-6.
25 390 34. Locatelli F, et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease.
26 391 *Nephrol Dial Transplant.* 2003;18:2-9.
27 392 35. Hamrahian SM, Falkner B. Hypertension in Chronic Kidney Disease. *Adv Exp Med Biol.*
28 393 2017;956:307-25.
29 394 36. World Health Organization. A global brief on hypertension: silent killer, global public health
30 395 crisis: World Health Day 2013. Geneva: 2013:1-39.
31 396 37. Xie X, et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in
32 397 Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. *Am J Kidney Dis.*
33 398 2016;67(5):728-41.
34 399 38. Ettehad D, et al. Blood pressure lowering for prevention of cardiovascular disease and death:
35 400 a systematic review and meta-analysis. *Lancet.* 2016;387(10022):957-67.
36 401 39. De Nicola L, et al. Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease:
37 402 Multicenter prospective study in Italy. *Nutrition Metabolism and Cardiovascular Diseases.*
38 403 2015;25(8):756-62.
39 404 40. Fabbian F, et al. Evidence-based statin prescription for cardiovascular protection in renal
40 405 impairment. *Clin Exp Nephrol.* 2011;15(4):456-63.
41 406 41. Grundy SM, et al. Management of Blood Cholesterol. *J Am Col Cardiol.* 2019;73(24):E285-
42 407 U87.
43 408 42. Wright RS, et al. Acute myocardial infarction and renal dysfunction: A high-risk combination.
44 409 *Annof Intern Med.* 2002;137(7):563-70.
45 410 43. Shlipak MG, et al. Association of renal insufficiency with treatment and outcomes after
46 411 myocardial infarction in elderly patients. *Ann Intern Med.* 2002;137(7):555-62.
47 412 44. Muntner P, et al. Renal insufficiency and subsequent death resulting from cardiovascular
48 413 disease in the United States. *J Am Soc Nephrol.* 2002;13(3).
49 414 45. Sultan AA, et al. Inside CKD: modelling the economic burden of chronic kidney disease in
50 415 Europe using patient-level microsimulation. *Nephrol Dial Transplant.* 2021;36:306.
51 416 46. Ivers N, Jet al. Audit and feedback: effects on professional practice and healthcare outcomes.
52 417 *Cochrane Database Syst Rev.* 2012(6).
53
54
55
56
57
58
59
60

1
2
3 418 47. Van den Bulck S, et al. The effect of electronic audits and feedback in primary care and
4 419 factors that contribute to their effectiveness: a systematic review. *Int J Qual Health Care*.
5 420 2020;32(10):708-20.
6

7 421

8
9 422 **Figure titles and legends:**

10 423

11
12
13 424 **Figure 1. Strata analysis for mortality**

14
15 425 Survival probability in different years grouped by CKD stage and presence of diagnostic code. Risk set table with
16 426 number of patients at risk per year.
17

18
19 427

20
21 428 **Figure 2. Strata analysis for cardiovascular disease**

22
23 429 Morbidity probability in different years grouped by CKD stage and presence of diagnostic code. Risk set table
24 430 with number of patients at risk per year.
25

26
27 431

28
29 432 **Figure 3. Mortality and time to event**

30
31 433 HRs and the 95% confidence interval (95% CI) for different variables. Systolic blood pressure (SBP), Body Mass
32 434 Index (BMI), cardiovascular disease (CVD).
33

34
35 435

36
37 436 **Figure 4. Cardiovascular disease with mortality as a competing risk**

38
39 437 sHRs and the 95% confidence interval (95% CI) for different variables. Systolic blood pressure (SBP), Body Mass
40 438 Index (BMI), cardiovascular disease (CVD).
41

42

43

44

45

46

47

48

49

50

51

52

53

54

55


56

57


58

59

60




	Number at risk					
	0	1	2	3	4	5
Registered CKD, stage 3A	1679	1608	1406	1085	640	77
Registered CKD, stage 3B	1210	1157	1021	831	585	117
Registered CKD, stage 4	387	358	308	245	170	46
Registered CKD, stage 5	99	87	70	51	33	14
Non-registered CKD, stage 3A	5699	5386	4601	3213	1604	155
Non-registered CKD, stage 3B	1221	1086	925	704	393	46
Non-registered CKD, stage 4	210	170	137	99	64	18
Non-registered CKD, stage 5	46	35	31	23	16	4




	Number at risk					
	0	1	2	3	4	5
Registered CKD, stage 3A	1679	1656	1500	1186	723	89
Registered CKD, stage 3B	1210	1192	1105	936	678	150
Registered CKD, stage 4	387	384	360	310	231	74
Registered CKD, stage 5	99	98	90	75	60	25
Non-registered CKD, stage 3A	5699	5631	4971	3593	1840	190
Non-registered CKD, stage 3B	1221	1192	1088	894	558	73
Non-registered CKD, stage 4	210	208	187	149	111	29
Non-registered CKD, stage 5	46	44	41	35	27	9
	0	1	2	3	4	5

Time (years)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Review only



Review only

Supplemental file 1: ATC codes

Antihypertensiva

- ACE inhibitors: C09A, C09B, or C10BX04, C10BX06, C10BX07, C10BX11, C10BX12, C10BX13, C10BX14, C10BX15, C10BX17, C10BX18 (combination)
- ARBs: C09C, C09D, or C10BX10, C10BX16 (combination)
- Angiotensin receptor-neprilysin inhibitor (ARNI): C09DX04
- Beta blockers: C07
- Calcium channel blockers: C08C, C08D, C08G, or C10BX03, C10BX07, C10BX09, C10BX11, C10BX14, C10BX18
- Alpha blockers, i.e., clonidine, moxonidine and methyldopa: C02AC01, C02AC05, C02AB
- Thiazide diuretics: C03A, or C10BX13
- Aldosterone receptor agonists (MRA): C03DA
- Loop diuretics: C03C

Lipid lowering medication

- C10

Antidiabetic drugs

- Metformin: A10BA02, or A10BD02, A10BD03, A10BD05, A10BD07, A10BD08, A10BD10, A10BD11, A10BD13, A10BD14, A10BD15, A10BD16, A10BD17, A10BD18, A10BD20, A10BD22, A10BD23, A10BD25, A10BD26 (combination)
- Sulphonylurea: A10BB, or A10BD01, A10BD02, A10BD04, A10BD06 (combination)
- Dipeptidyl peptidase 4 inhibitors (DPP-4i): A10BH, or A10BD07, A10BD08, A10BD09, A10BD10, A10BD11, A10BD12, A10BD13 (combination)
- Glucagon-like peptide-1 receptor agonist (GLP1-RA): A10BJ
- Insulin: A10AB, A10AC, A10AD, A10AE
- SGLT2s: A10BK01, A10BK02, A10BK03, A10BK04 or A10BD15, A10BD16, A10BD19, A10BD20, A10BD21, A10BD23, A10BD24, A10BD25 (in combination)
- Other oral anti-diabetic (OADs); Pioglitazon, acarbose, repaglinide: A10BG03, A10BF01, A10BX02, or A10BD05, A10BD06, A10BD12, A10BD14, A10BD17 (combination)


Supplemental file 2: Missing variables

Variable	Missingness
Total patients	10551
Smoking	75.98%
SBP	7.89%
Total Cholesterol	15.2%
BMI	55.34%

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplemental file 3: Flow chart of the study population



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5
		(b) For matched studies, give matching criteria and number of exposed and unexposed	/
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	5-7
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	7
		(d) If applicable, explain how loss to follow-up was addressed	Not applicable
		(e) Describe any sensitivity analyses	Not applicable
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	Additional file 2
		(c) Summarise follow-up time (eg, average and total amount)	8
Outcome data	15*	Report numbers of outcome events or summary measures over time	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8-9
		(b) Report category boundaries when continuous variables were categorized	Not applicable
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8-9
Discussion			
Key results	18	Summarise key results with reference to study objectives	10
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.